Epothilones and new analogues of the microtubule modulators in taxane-resistant disease

Bibliography

• Swanton C, Marani M, Pardo O, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007;11(6):498-512
   PubMed Web of Science ®Google Scholar
• Vogel C, Kienitz A, Hofmann I, et al. Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 2004;23:6845-53
   PubMed Web of Science ®Google Scholar
• Masuda A, Maeno K, Nakagawa T, et al. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 2003;163(3):1109-16
   PubMed Web of Science ®Google Scholar
• Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004;64(7):2502-8
   PubMedGoogle Scholar
• Swanton C, Tomlinson I, Downward J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 2006;5(8):818-23
   PubMed Web of Science ®Google Scholar
• Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint genes in human cancers. Nature 1998;392(6673):300-3
   PubMed Web of Science ®Google Scholar
• Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003;3(1):51-62
   PubMed Web of Science ®Google Scholar
• Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005;5(10):773-85
   PubMed Web of Science ®Google Scholar
• Inaba S, Li C, Shi YE, et al. Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells. Breast Cancer Res Treat 2005;94(1):25-35
   PubMed Web of Science ®Google Scholar
• Wang Z, Cummins JM, Shen D, et al. Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Res 2004;64(9):2998-3001
   PubMed Web of Science ®Google Scholar
• Hauf S, Cole RW, LaTerra S, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003;161(2):281-94
   PubMed Web of Science ®Google Scholar
• Michel LS, Liberal V, Chatterjee A, et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001;409(6818):355-9
   PubMed Web of Science ®Google Scholar
• Baker DJ, Jeganathan KB, Cameron JD, et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet 2004;36(7):744-9
   PubMed Web of Science ®Google Scholar
• Dai W, Wang Q, Liu T, et al. Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer Res 2004;64(2):440-5
   PubMed Web of Science ®Google Scholar
• Iwanaga Y, Chi YH, Miyazato A, et al. Heterozygous deletion of mitotic arrest-deficient protein 1 (MAD1) increases the incidence of tumors in mice. Cancer Res 2007;67(1):160-6
   PubMed Web of Science ®Google Scholar
• Babu JR, Jeganathan KB, Baker DJ, et al. Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. J Cell Biol 2003;160(3):341-53
   PubMed Web of Science ®Google Scholar
• Wang X, Zhou YX, Qiao W, et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 2006;25(54):7148-58
   PubMed Web of Science ®Google Scholar
• Hanks S, Coleman K, Reid S, et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet 2004;36(11):1159-61
   PubMed Web of Science ®Google Scholar
• Matsuura S, Ito E, Tauchi H, et al. Chromosomal instability syndrome of total premature chromatid separation with mosaic variegated aneuploidy is defective in mitotic-spindle checkpoint. Am J Hum Gen 2000;67(2):483-6
   PubMed Web of Science ®Google Scholar
• Carter SL, Eklund AC, Kohane IS, et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006;38(9):1043-8
   PubMed Web of Science ®Google Scholar
• Bayliss R, Sardon T, Vernos I, Conti E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell 2003;12(4):851-62
   PubMed Web of Science ®Google Scholar
• Jones AM, Douglas EJ, Halford SE, et al. Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinoma. Oncogene 2005;24(1):118-29
   PubMed Web of Science ®Google Scholar
• Nishida N, Nagasaka T, Kashiwagi K, et al. High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther 2007;6(4):525-33
   PubMed Web of Science ®Google Scholar
• Miyoshi Y, Iwao K, Egawa C, Noguchi S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 2001;92(3):370-3
   PubMed Web of Science ®Google Scholar
• Yoon DS, Wersto RP, Zhou W, et al. Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. Am J Pathol 2002;161(2):391-7
   PubMed Web of Science ®Google Scholar
• Gascoyne DM, Hixon ML, Gualberto A, Vivanco MD. Loss of mitotic spindle checkpoint activity predisposes to chromosomal instability at early stages of fibrosarcoma development. Cell Cycle 2003;2(3):238-45
   PubMedGoogle Scholar
• Saeki A, Tamura S, Ito N, et al. Frequent impairment of the spindle assembly checkpoint in hepatocellular carcinoma. Cancer 2002;94(7):2047-54
   PubMed Web of Science ®Google Scholar
• Minhas KM, Singh B, Jiang WW, et al. Spindle assembly checkpoint defects and chromosomal instability in head and neck squamous cell carcinoma. Int J Cancer 2003;107(1):46-52
   PubMed Web of Science ®Google Scholar
• Ohshima K, Haraoka S, Yoshioka S, et al. Mutation analysis of mitotic checkpoint genes (hBUB1 and hBUBR1) and microsatellite instability in adult T-cell leukemia/lymphoma. Cancer Lett 2000;158(2):141-50
   PubMed Web of Science ®Google Scholar
• Kasai T, Iwanaga Y, Iha H, Jeang KT. Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors. J Biol Chem 2002;277(7):5187-93
   PubMed Web of Science ®Google Scholar
• Boyapati A, Yan M, Peterson LF, et al. A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy. Blood 2007;109:3963-71
   PubMed Web of Science ®Google Scholar
• Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55(11):2325-33
   PubMed Web of Science ®Google Scholar
• Nehme A, Varadarajan P, Sellakumar G, et al. Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells. Br J Cancer 2001;84(11):1571-6
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Prolonged mitosis versus tetraploid checkpoint: how p53 measures the duration of mitosis. Cell Cycle 2006;5(9):971-5
   PubMed Web of Science ®Google Scholar
• Hagisawa S, Mikami T, Sato Y. Docetaxel-induced apoptosis in the mitotic phase: electron microscopic and cytochemical studies of human leukemia cells. Med Electron Microsc 1999;32(3):167-74
   PubMedGoogle Scholar
• Morse DL, Gray H, Payne CM, Gillies RJ. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 2005;4(10):1495-504
   PubMed Web of Science ®Google Scholar
• Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res 2003;63(18):6026-31
   PubMed Web of Science ®Google Scholar
• Chen JG, Yang CP, Cammer M, Horwitz SB. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 2003;63(22):7891-9
   PubMed Web of Science ®Google Scholar
• Bergstralh DT, Taxman DJ, Chou TC, et al. A comparison of signaling activities induced by Taxol and desoxyepothilone B. J Chemother 2004;16(6):563-76
   PubMed Web of Science ®Google Scholar
• Chen JG, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 2002;62(7):1935-8
   PubMed Web of Science ®Google Scholar
• Broker LE, Huisman C, Span SW, et al. Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res 2004;64(1):27-30
   PubMed Web of Science ®Google Scholar
• Ferguson RE, Jackson SM, Stanley AJ, et al. Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Int J Cancer 2005;115(1):155-63
   PubMed Web of Science ®Google Scholar
• Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272(27):17118-25
   PubMed Web of Science ®Google Scholar
• Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7(5):1429-37
   PubMed Web of Science ®Google Scholar
• Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 2000;97(6):2904-9
   PubMed Web of Science ®Google Scholar
• Wang Y, O'Brate A, Zhou W, Giannakakou P. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle 2005;4(12):1847-53
   PubMed Web of Science ®Google Scholar
• Berrieman H, Lind M, Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004;5:158-64
   PubMed Web of Science ®Google Scholar
• Mesquita B, Veiga I, Pereira D, et al. No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer 2005;5:101
   PubMed Web of Science ®Google Scholar
• Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003;21(9):1866-73
   PubMed Web of Science ®Google Scholar
• Widemann BC, Fox E, Goodspeed WJ, et al. Phase I trial of the epothilone B analog BMS-247550 (ixabepilone) in children with refractory solid tumors [abstract]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Zhuang SH, Agrawal M, Edgerly M, et al. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005;103(9):1932-8
   PubMed Web of Science ®Google Scholar
• Burris HA. Phase I study of the novel epothilone BMS-247550 administered weekly in patients with advanced malignancies [abstract]. Proc Am Soc Clin Oncol 2002
   Google Scholar
• Dickson N. Ixabepilone given weekly in patients with advanced malignancies: final efficacy and safety results of a phase I trial. 42nd ASCO Annual Meeting; 2006 June; Atlanta, GA, USA
   Google Scholar
• Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004;10(4):1289-98
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Wozniak A, Boinpally RR, et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 2005;11(17):6233-9
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Burris HA 3rd, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007;25(9):1082-8
   PubMed Web of Science ®Google Scholar
• Shimizu T, Yamamoto N, Yamada Y, et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol 2008;61:751-8
   PubMed Web of Science ®Google Scholar
• Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25(23):3399-406
   PubMed Web of Science ®Google Scholar
• Roche H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25(23):3415-20
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Lara PN Jr, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007;25(23):3448-55
   PubMed Web of Science ®Google Scholar
• Ajani JA, Safran H, Bokemeyer C, et al. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs 2006;24(5):441-6
   PubMed Web of Science ®Google Scholar
• Whitehead RP, McCoy S, Rivkin SE, et al. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study. Invest New Drugs 2007;24:515-20
   Web of Science ®Google Scholar
• Eng C, Kindler HL, Nattam S, et al. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 2004;15(6):928-32
   PubMed Web of Science ®Google Scholar
• Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25(23):3421-7
   PubMed Web of Science ®Google Scholar
• Denduluri N, Lee JJ, Walshe J, et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 2007;25(1):63-7
   PubMed Web of Science ®Google Scholar
• Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25(23):3407-14
   PubMed Web of Science ®Google Scholar
• Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23(12):2726-34
   PubMed Web of Science ®Google Scholar
• Baselga J. Predicting response to Ixabepilone: genomics study in patients receiving single agent Ixabepilone as neoadjuvant treatment for breast cancer (BC) [abstract 305]. 28th San Antonio Breast Cancer Symposium; 2005
   Google Scholar
• Vahdat LT. Phase III trial of Ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes [abstract 1006]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• Hussain M, Tangen CM, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23(34):8724-9
   PubMed Web of Science ®Google Scholar
• Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23(7):1439-46
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110(3):556-63
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Galsky MD, Rohs NC, et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer 2006;106(1):58-62
   PubMed Web of Science ®Google Scholar
• Liu G. A phase II study of a weekly schedule of BMS-247550 for patients with hormone-refractory prostate cancer: A trial of the Eastern Cooperative Oncology Group (E3803) [abstract 4618]. 42nd ASCO Annual Meeting; 2006 June; Atlanta, GA, USA
   Google Scholar
• Dreicer R, Li S, Manola J, et al. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the eastern cooperative oncology group. Cancer 2007;110(4):759-63
   PubMed Web of Science ®Google Scholar
• Zhuang SH. A Phase II clinical trial of BMS-247550 (Ixabepilone), a microtubule-stabilizing agent in renal cell cancer [abstract 4550]. 40th ASCO Annual Meeting; 2004 June; New Orleans, LA, USA
   Google Scholar
• Posadas EM, Undevia S, Manchen E, et al. A phase II Study of Ixabepilone (BMS-247550) in Metastatic Renal-Cell Carcinoma. Cancer Biol Ther 2007;6(4)
   PubMedGoogle Scholar
• O'Connor O. Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone anlog BMS 247550 induces major and durable remissions in very drug resistant disease [abstract 6569]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Smith SM. A Phase II study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-hodgkin's lymphomas [abstract 6625]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Okuno S, Maples WJ, Mahoney MR, et al. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium. J Clin Oncol 2005;23(13):3069-73
   PubMed Web of Science ®Google Scholar
• Singh D. A phase II trial of the epothilone B analog BMS-247550 in patients (pts) with hepatobiliary cancer (HBC): an updated analysis [abstract 14050]. 42nd ASCO Annual Meeting; 2006 June; Atlanta, GA, USA
   Google Scholar
• Feldman DR, Kondagunta GV, Ginsberg MS, et al. Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Invest New Drugs 2007;25(5):487-90
   PubMed Web of Science ®Google Scholar
• Burtness B. A randomized phase II study of BMS-247550 (Ixabepilone) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck [abstract 5532]. 42nd ASCO Annual Meeting; 2006 June; Atlanta, GA, USA
   Google Scholar
• Pavlick AC. A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM) [abstract 7542]. 40th ASCO Annual Meeting; 2004 June; New Orleans, LA, USA
   Google Scholar
• Hensley ML, Dizon D, Derosa F, et al. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs 2007;25(4):335-41
   PubMed Web of Science ®Google Scholar
• Plummer R. Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced solid malignancies [abstract 2125]. Proc Am Soc Clin Oncol 2002
   PubMedGoogle Scholar
• Moulder SL. A phase II trial of trastuzumab, weekly Ixabepilone and carboplatin (TIC) in patients with HER2/neu-positive (HER2+) metastatic breast cancer (MBC): a trial coordinated by the Eastern Cooperative Oncology Group (E2103) [abstract6070]. 40th ASCO Annual Meeting; 2004 June; New Orleans, LA, USA
   Google Scholar
• Chuang E, et al. Phase I clinical trial of Ixabepilone and pegylated liposomal doxorubicin in patients with advanced breast or ovarian cancers: New York Cancer Consortium Trial P7229 [abstract 2570]. Proc Am Soc Clin Oncol 2007;25(18S)
   Google Scholar
• Faivre SJ. Phase I study of ixabepilone given every other week in combination with irinotecan in patients with advanced malignancies [abstract 2051]. 2004
   Google Scholar
• Rosenberg JE. NCI 7347: Phase I/II trial of epothilone analog BMS-247550 (Ixabepilone), mitoxantrone, and prednisone in hormone refractory prostate cancer patients previously treated with chemotherapy [abstract 266]. Prostate Cancer Symp 2007
   Google Scholar
• Melichar B, Casado E, Taberno J, et al. Patupilone in chemotherapy-pretreated patients with advanced colorectal cancer (CRC) receiving nutritional support and intensive diarrhea management: a phase I multicenter trial [abstract 8198]. ESMO, Istanbul; 2006
   Google Scholar
• Rubin EH, Rothermel J, Tesfaye F, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005;23(36):9120-9
   PubMed Web of Science ®Google Scholar
• Sanchez JM. Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): a phase I/II trial [abstract 7104]. 42nd ASCO Annual Meeting; 2006 June; Atlanta, GA, USA
   Google Scholar
• Smit WM. Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with resistant/refractory ovarian cancer. Eur J Cancer 2005;3(2):261
   Google Scholar
• Calvert PM. A phase I clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors [abstract 429]. Proc Am Soc Clin Oncol 2001
   Google Scholar
• Poplin E. Safety and efficacy of EPO906 in patients with advanced colorectal cancer: a review of 2 phase II trials [abstract 1135]. 39th ASCO Annual Meeting; 2003 May–June; Chicago, IL, USA
   Google Scholar
• Hussain A. A phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC) [abstract 4563]. ASCO Annual Meeting Proceedings; 2004
   Google Scholar
• Thompson JA. Phase II trial evaluating the safety and efficacy of EPO906 in patients with advanced renal cancer [abstract 1628]. Proc Am Soc Clin Oncol 2003
   Google Scholar
• Venook AP. Evaluation of patupilone as monotherapy in patients with advanced hepatocellular carcinoma (HCC) [abstract 15055]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• Hsin KW. Efficacy of patupilone in advanced local or metastatic gastric cancer: a phase IIa trial [abstract 4069]. 42nd ASCO Annual Meeting; 2006 June; Atlanta, GA, USA
   Google Scholar
• Anthony LB. An open-label phase IIA trial evaluating the safety and efficacy of EPO906 as therapy in patients with metastatic carcinoid and other neuroendocrine tumors [abstract 1413]. Proc Am Soc Clin Oncol 2003
   Google Scholar
• Forster M, Kaye S, Oza A, et al. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin Cancer Res 2007;13(14):4178-84
   PubMed Web of Science ®Google Scholar
• Rinehart JJ. Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus gemcitabine in patients with advanced cancer [abstract 3100]. Proc Am Soc Clin Oncol 2004
   PubMedGoogle Scholar
• Dumez H. Phase Ib/II dose-escalation trial evaluating the safety and tolerability of EPO906 plus capecitabine in patients with advanced cancer [abstract 2093]. ASCO Annual Meeting Proceedings; 2004
   Google Scholar
• Wojtowicz M. Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus estramustine in patients with advanced cancer [abstract 4623]. Proc Am Soc Clin Oncol 2004
   Google Scholar
• Spriggs D. KOS-862 (Epothilone D): Phase 1 dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies [abstract 894]. Proc Am Soc Clin Oncol 2003
   Google Scholar
• Holen KD. Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. [abstract 2024]. Proc Am Soc Clin Oncol 2004
   Google Scholar
• Piro LD. KOS-862 (epothilone D): a comparison of two schedules in patients with advanced malignancies [abstract 539]. Proc Am Soc Clin Oncol 2003;22
   Google Scholar
• Beer TM, Higano CS, Saleh M, et al. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 2007;25:565-70
   PubMed Web of Science ®Google Scholar
• Buzdar AU. A phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: updated results [abstract 1087]. 28th San Antonio Breast Cancer Symposium; 2005
   Google Scholar
• Yee L. A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer [abstract 7127]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA; 23(16S)
   Google Scholar
• Monk JP. Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors [abstract 2049]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Marshall JL. Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors [abstract 2041]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Cortes J. A phase I trial of weekly combination KOS-862 (Epothilone D) and trastuzumab in HER-2 overexpressing malignancies [abstract 2028]. 42nd ASCO Annual Meeting; 2006 June; Atlanta, GA, USA
   Google Scholar
• Schmid P. A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors [abstract 2051]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Rustin G. Phase II trial of the novel epothilone ZK-EPO in patients with platinum resistant ovarian cancer [abstract 5527]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• Gatzemeier U. Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non small cell lung cancer [abstract 6568]. ECCO; 2007. p. 378
   Google Scholar
• Sessa C, Perotti A, Llado A, et al. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol 2007;18(9):1548-53
   PubMed Web of Science ®Google Scholar
• Mekhail T. Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days [abstract 515]. Proc Am Soc Clin Oncol 2003
   PubMedGoogle Scholar
• Villalona-Calero M. First-in-human phase I trial of a novel epothilone, KOS-1584 [abstract 2003]. 42nd ASCO Annual Meeting; 2006 June; Atlanta, GA, USA
   Google Scholar
• Stopeck A. Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules [abstract 2041]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• Hoffman MA, Blessing JA, Lentz SS. A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003;89(1):95-8
   PubMed Web of Science ®Google Scholar
• Kindler HL, Tothy PK, Wolff R, et al. Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs 2005;23(5):489-93
   PubMed Web of Science ®Google Scholar
• Krug LM, Miller VA, Kalemkerian GP, et al. Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Ann Oncol 2000;11(2):227-8
   PubMed Web of Science ®Google Scholar
• Margolin K, Longmate J, Synold TW, et al. Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. Invest New Drugs 2001;19(4):335-40
   PubMed Web of Science ®Google Scholar
• Perez EA, Hillman DW, Fishkin PA, et al. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs 2005;23(3):257-61
   PubMed Web of Science ®Google Scholar
• Saad ED, Kraut EH, Hoff PM, et al. Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Am J Clin Oncol 2002;25(5):451-3
   PubMed Web of Science ®Google Scholar
• Vaishampayan U, Glode M, Du W, et al. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res 2000;6(11):4205-8
   PubMed Web of Science ®Google Scholar
• Kerbrat P, Dieras V, Pavlidis N, et al. Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer. Eur J Cancer 2003;39(3):317-20
   PubMed Web of Science ®Google Scholar
• Marks RS, Graham DL, Sloan JA, et al. A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer. Am J Clin Oncol 2003;26(4):336-7
   PubMed Web of Science ®Google Scholar
• Smyth J, Boneterre ME, Schellens J, et al. Activity of the dolastatin analogue, LU103793, in malignant melanoma. Ann Oncol 2001;12(4):509-11
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Natsume T, Tamaoki S, et al. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 1997;88(3):316-27
   PubMedGoogle Scholar
• Watanabe J, Natsume T, Fujio N, et al. Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis 2000;5(4):345-53
   PubMed Web of Science ®Google Scholar
• Natsume T, Watanabe J, Koh Y, et al. Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo. Cancer Sci 2003;94(9):826-33
   PubMed Web of Science ®Google Scholar
• Patel S, Keohan ML, Saif MW, et al. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 2006;107(12):2881-7
   PubMed Web of Science ®Google Scholar
• Riely GJ, Gadgeel S, Rothman I, et al. A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer 2007;55(2):181-5
   PubMed Web of Science ®Google Scholar
• Greystoke A, Blagden S, Thomas AL, et al. A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Ann Oncol 2006;17(8):1313-9
   PubMed Web of Science ®Google Scholar
• Stephenson K. ILX651 disrupts microtuble assembly by two mechanisms [abstract 5616]. Proc Am Assoc Cancer Res 2004
   Google Scholar
• Mcdermott DF. ILX651 administered daily for five days every 3 weeks (qd×5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma: phase II experience [abstract 7556]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4(7):1086-95
   PubMed Web of Science ®Google Scholar
• Spira AI. Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC) [abstract 7546]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• Blum J. E7389, a novel anti-tubulin, in patients with refractory breast cancer [abstract 653]. 42nd ASCO Annual Meeting; 2006 June; Atlanta, GA, USA
   Google Scholar
• Molife R. Phase II multicenter, two-stage study of E7389 in patients with hormone refractory prostate cancer with advanced and/or metastatic disease stratified by prior chemotherapy [abstract 5513]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• Blum J. Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer [abstract 1034]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• Ratain MJ. Phase 1 and pharmacological study of HTI-286, a novel antimicrotubule agent: correlation of neutropenia with time above a threshold serum concentration [abstract 516]. Proc Am Soc Clin Oncol 2003
   Google Scholar
• Kuznetsov G. Tubulin-based antimitotic mechanism of novel hemiasterlin analog E7974 [abstract 2550]. Proc Am Assoc Cancer Res 2005
   Google Scholar
• Madajewicz S. A phase I trial of E7974 administered on days 1 and 15 of a 28-day cycle in patients with solid malignancies [abstract 2550]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• Zojwalla NJ. A phase I trial of E7974 administered on days 1, 8, and 15 of a 28-day cycle in patients with solid malignancies [abstract 2543]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• D'Agostino G, del Campo J, Mellado B, et al. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. Int J Gynecol Cancer 2006;16(1):71-6
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Gandara DR, Hausner P, et al. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2003;39(2):197-9
   PubMed Web of Science ®Google Scholar
• Sauter A, Kloft C, Gronau S, et al. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 2007;30(4):927-35
   PubMed Web of Science ®Google Scholar
• Tijink BM, Buter J, de Bree R, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006;12(20 Pt 1):6064-72
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Ochoa L, Hammond LA, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21(2):211-22
   PubMed Web of Science ®Google Scholar
• Fosella F. Phase II Trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma [abstract 7159]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Beeram M. A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC) [abstract 1042]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• Milowsky MI. Phase 1/2 dose escalation trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer (CRPC) [abstract 4615]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Dupont J, Bienvenu B, Aghajanian C, et al. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors. J Clin Oncol 2004;22(16):3366-74
   PubMed Web of Science ®Google Scholar
• Salazar R, Bissett D, Twelves C, et al. A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors. Clin Cancer Res 2004;10(13):4374-82
   PubMed Web of Science ®Google Scholar
• Miller K. Phase II study of MKC-1 in patients with metastatic breast cancer previously treated with an anthracycline and a taxane [abstract 234]. ASCO Breast Cancer Symp 2007
   Google Scholar
• Yoshimatsu K, Yamaguchi A, Yoshino H, et al. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997;57(15):3208-13
   PubMed Web of Science ®Google Scholar
• Washington DK. Phase 2 results of ABT-751 in subjects with taxane-refractory breast cancer: interim analysis [abstract 724]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Benson AB. Phase 2 Study of ABT-751 in Patients with Refractory Metastatic Colorectal Carcinoma (CRC) [abstract 3537]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Mauer A. Preliminary results of a phase 2 study of ABT-751 in patients (pts) with taxane-refractory Non-small Cell Lung Carcinoma (NSCLC) [abstract 7137]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Hagey A. Preliminary phase 2 results of ABT-751 in subjects with advanced Renal Cell Carcinoma (RCC) [abstract 4603]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Shan B, Medina JC, Santha E, et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci USA 1999;96(10):5686-91
   PubMed Web of Science ®Google Scholar
• Molpus K. A Phase I study of the anti-microtubule agent T138067-sodium administered daily x 5 every 3 weeks [abstract 415]. Proc Am Soc Clin Oncol 2002
   Google Scholar
• Donehower RC. A phase I pharmacokinetic study of T138067 administered as a Weekly 3-hour infusion [abstract 438]. Proc Am Soc Clin Oncol 2001
   PubMedGoogle Scholar
• Spriggs D. A phase I and pharmacology study of the novel antimicrotubule depolymerising agent T138067 [abstract 921]. Proc Am Soc Clin Oncol 2000
   Google Scholar
• Kirby S, Gertler SZ, Mason W, et al. Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group. Neuro oncol 2005;7(2):183-8
   PubMed Web of Science ®Google Scholar
• Posey J. Results of a phase 2/3 open-label, randomized trial of T138067 versus doxorubicin (DOX) in chemotherapy-naïve, unresectable hepatocellular carcinoma (HCC) [abstract 4035]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Garrett C. A phase II study of T900607 (T607) in subjects with chemotherapy-naïve unresectable hepatocellular carcinoma (HCC) [abstract 4125]. 40th ASCO Annual Meeting; 2004 June; New Orleans, LA, USA
   Google Scholar
• Heath EL. A phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors [abstract 2026]. 42nd ASCO Annual Meeting; 2006 June; Atlanta, GA, USA
   Google Scholar
• Chu QS. A phase I trial of novel kinesin spindle protein (KSP) inhibitor, SB-715992 administered intravenously once every 21 days [abstract 2078]. 40th ASCO Annual Meeting; 2004 June; New Orleans, LA, USA
   Google Scholar
• Burris HA. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days [abstract 2004]. 40th ASCO Annual Meeting; 2004 June; New Orleans, LA, USA
   Google Scholar
• Lee CW, Belanger K, Rao SC, et al. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2007 [Epub ahead of print]
   Google Scholar
• Beekman KW. University of Chicago Consortium phase II study of ispinesib (SB-715992) in patients (pts) with advanced renal cell carcinoma (RCC) [abstract 15573]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• Shahin MS. A phase II, open-label study of ispinesib (SB-715992) in patients with platinum/taxane refractory or resistant relapsed ovarian cancer [abstract 5562]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• El-Khoueiry AB. A randomized phase II non-comparative study of ispinesib given weekly or every three weeks in metastatic colorectal cancer. A California Cancer Consortium Study (CCC-P) [abstract 5562]. 42nd ASCO Annual Meeting; 2006 June; Atlanta, GA, USA
   Google Scholar
• Tang PA, Siu LL, Chen EX, et al. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2007 [Epub ahead of print]
   PubMedGoogle Scholar
• Goy A. A phase I-II study to assess the safety, pharmacokinetics, and potential efficacy of intravenous SB-743921 on days 1 and 15 of a 28-day cycle in patients with non-Hodgkin lymphoma [abstract 18516]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• Holen KD. Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor [abstract 2000]. 2006
   Google Scholar
• Stein M. Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in patients with solid tumors [abstract 2548]. 43rd ASCO Annual Meeting; 2007 June; Chicago, IL, USA
   Google Scholar
• Desai A. A phase 1, dose-escalation trial of STA-5312, a microtubule inhibitor with a novel binding site, in advanced or metastatic solid malignancies [abstract 13040]. 42nd ASCO Annual Meeting; 2006 June; Atlanta, GA, USA
   Google Scholar
• Seibel NL, Blaney SM, O'Brien M, et al. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res 1999;5(4):733-7
   PubMed Web of Science ®Google Scholar
• Taguchi T. An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract. Gan To Kagaku Ryoho 1994;21(14):2431-7
   PubMedGoogle Scholar
• Rice A, Michaelis ML, Georg G, et al. Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors. J Mol Neurosci 2003;20(3):339-43
   PubMed Web of Science ®Google Scholar
• Tamura K, Nakagawa K, Kurata T, et al. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses. Cancer Chemother Pharmacol 2007;60(2):285-93
   PubMed Web of Science ®Google Scholar
• de Jonge MJ, van der Gaast A, Planting AS, et al. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 2005;11(10):3806-13
   PubMed Web of Science ®Google Scholar
• Schoffski P, Thate B, Beutel G, et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 2004;15(4):671-9
   PubMed Web of Science ®Google Scholar
• Mita AC, Hammond LA, Bonate PL, et al. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin Cancer Res 2006;12(17):5207-15
   PubMed Web of Science ®Google Scholar
• Cunningham C, Appleman LJ, Kirvan-Visovatti M, et al. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2005;11(21):7825-33
   PubMed Web of Science ®Google Scholar
• Ebbinghaus S, Rubin E, Hersh E, et al. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2005;11(21):7807-16
   PubMed Web of Science ®Google Scholar
• Synold TW. A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial [abstract 3036]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Rubin EH. Phase I study of E7389 administered by 1 hour infusion every 21 days [abstract 2054]. 41st ASCO Annual Meeting; 2005 May; Orlando, FL, USA
   Google Scholar
• Sessa C, Weigang-Kohler K, Pagani O, et al. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule. Eur J Cancer 2002;38(18):2388-96
   PubMed Web of Science ®Google Scholar
• Stevenson JP, Sun W, Gallagher M, et al. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. Clin Cancer Res 2002;8(8):2524-9
   PubMed Web of Science ®Google Scholar
• Helft PR, Schilsky RL, Hoke FJ, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res 2004;10(13):4363-8
   PubMed Web of Science ®Google Scholar
• Fox E, Maris JM, Widemann BC, et al. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006;12(16):4882-7
   PubMed Web of Science ®Google Scholar
• Hande KR, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 2006;12(9):2834-40
   PubMed Web of Science ®Google Scholar
• Yee KW, Hagey A, Verstovsek S, et al. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005;11(18):6615-24
   PubMed Web of Science ®Google Scholar
• Lockhart AC. T900607-sodium administered daily × 5 as a 60-minute infusion every 3 weeks: a phase I study of T900607-sodium in patients (pts) with refractory cancer [abstract 417]. Proc Am Soc Clin Oncol 2002
   Google Scholar
• Stagg RJ. A phase I study of T900607-sodium administered weekly in patients with refractory cancer [abstract 416]. Proc Am Soc Clin Oncol 2002
   PubMedGoogle Scholar
• Gelmon KA, Belanger K, Soulieres D, et al. A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130. Invest New Drugs 2005;23(5):445-53
   PubMed Web of Science ®Google Scholar
• Burris H 3rd, Yardley D, Jones S, et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004;22(9):1621-9
   PubMed Web of Science ®Google Scholar